BioSpace News Archive

Hutchison China MediTech Limited has initiated FRESCO-2, a Phase III registration study of fruquintinib for the treatment of patients with metastatic colorectal cancer in the U.S., Europe and Japan.

Oncopeptides AB announces that the last patient has been successfully enrolled in the pivotal phase 3 study OCEAN in relapsed refractory multiple myeloma.

Alligator Bioscience announced biomarker data from a recently performed clinical Phase I study of the drug candidate mitazalimab, its wholly owned CD40 antibody in development primarily for the treatment of pancreatic cancer.

Yiling Pharmaceutical on Friday issued a notice that it had received a certificate of drug registration granted by the Pharmaceutical and Herbal Medicine Registration and Control Administration of Kuwait that certified its drug - Lianhua Qingwen Capsules - as a herbal medicine to be registered in Kuwait.

RhoVac AB (“RhoVac”) announces today September 4 th 2020, that it is continuing to strengthen the Scientific Advisory Board with a pediatric immunologist, by appointing Professor Georg Holländer , Action Research Professor and Head of Department at Oxford University , UK and Professor in Development Immunology, ETH Zurich, Sw

Electromedical Technologies, Inc. is pleased to announce that the Financial Industry Regulatory Authority, Inc. has approved the Company’s official symbol change to “EMED”.

Mesoblast Limited announced that the independent Data Safety Monitoring Board recommended continuation of the Phase 3 trial of remestemcel-L in patients with moderate to severe acute respiratory distress syndrome due to COVID-19 infection, following completion of trial’s first interim analysis.

Seoul Viosys, a leading compound semiconductor solution provider, announced that it has developed an optimal module designed to sterilize 99.9% of the coronavirus in 3 seconds using “Violeds”, a UV LED technology, and started mass production.

On August 25, 111, Inc., a company dedicated to digitally connecting patients with drugs and healthcare services in China, and Guangzhou Baiyunshan Pharmaceutical Sales Co., Ltd., an affiliate of Guangzhou Pharmaceuticals Corporation, signed a strategic cooperation agreement in Shanghai.

Merck, known as MSD outside the United States and Canada, announced that Dr. Roy Baynes, senior vice president and head of global clinical development, chief medical officer, Merck Research Laboratories, is scheduled to participate in a fireside chat at the Citi 15th Annual BioPharma Virtual Conference on Sept. 10, 2020, at 8:00 a.m. EDT.